The reported therapeutic targets, such as integrins, vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), angiopoietin-2 (ANGPT2), E-selectin, the transcription factor Yin Yang 1 (YY1) and invasive endothelial cells (ECS) [16–20], can be inhibited by drugs like lenvatinib and propranolol, to delay tumor angiogenesis [17, 21]. Here, PDGFRA is linked to neoplasm.